Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.66 |
| ▸ | GBA1 | P04062 | 12/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25516156 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL94371 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL25818947 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL19501713 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL11318961 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL19663777 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL15944228 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL15203072 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL21959579 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 | |
| SCHEMBL25516157 | 1.00 | HRH4 (0.66) | HRH4HRH3GBA1CYP19A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | HRH4 2639/4885HRH3 2900/4885GBA1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.